News >

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

Brittany Cote
Published: Thursday, Apr 09, 2020

Pazopanib (Votrient) plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.1

Results showed that 45% of patients had a partial response with the combination, 30% achieved stable disease, and 25% experienced disease progression. The median progression-free survival (PFS) was 5.5 months with pazopanib plus cyclophosphamide and the median overall survival was 9.5 months.

“This analysis presents a measure of effectiveness of the pazopanib and cyclophosphamide combination in patients with platinum-resistant or -refractory [epithelial ovarian cancer] in a real- world setting,” Seema Gulia, MD, DM, of Tata Memorial Centre, and her co-investigators wrote. “Our results suggest that this combination is associated with a clinically meaningful objective response, clinical benefit, and PFS benefit in a heavily pretreated patient population.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication